In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Analyst Joel Beatty of Robert W. Baird maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of ...

We recently compiled a list of the 10 Worst-Performing Growth Stocks in 2024. In this article, we are going to take a look at ...

Acadia Pharmaceuticals ACAD reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate ...

On Monday, ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $14.62 which represents a decrease of $-0.19 or -1.28% from the prior close of $14.81. The stock opened at $14.73 ...

ACADIA Pharmaceuticals Inc (ACAD) reports an 18% increase in net sales and outlines promising growth strategies amidst challenges in product penetration and patient adherence.

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...